Lilly’s Olumiant Cuts COVID-19 Hospital Stays By One Day

Company Will Seek An EUA For Baricitinib Plus Remdesivir

 
• By Mandy Jackson
  
Generate a summary of this article
Listen to this article
Beta

Olumiant (baricitinib) plus Gilead’s Veklury (remdesivir) provided a statistically significant reduction in time to recovery versus remdesivir alone for hospitalized patients in US NIAID’s ACTT-2 clinical trial. 

coronavirus covid 19 infected patient in quarantine room with quarantine and outbreak alert sign at hospital with coronavirus covid 19 disease control experts make coronavirus disease treatment
Olumiant/Veklury bested Veklury alone in hospitalized COVID-19 patients • Source: Shutterstock

Eli Lilly and Company plans to seek an emergency use authorization from the US Food and Drug Administration and similar go-aheads in other countries for Olumiant (baricitinib) in the treatment of hospitalized COVID-19 patients based on results from a US National Institute of Allergy and Infectious Disease study of the JAK1/2 inhibitor in combination with Gilead Sciences, Inc.’s Veklury (remdesivir).

Olumiant, which showed a statistically significant improvement versus remdesivir alone in time to recovery, was developed under a partnership with...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from COVID-19

New COVID-19 Vaccines Shipping Soon, After Rapid Pivot To Address New Strain

 
• By Alaric DeArment

Pfizer/BioNTech and Moderna rapidly adapted Comirnaty and Spikevax for the 2024-2025 season to address the KP.2 variant after the US FDA had advised them to target JN.1 in June.

Pfizer/BioNTech Combo Vaccine Shows Partial Flu Efficacy

 
• By Alaric DeArment

The companies said their combination mRNA vaccine showed protection against SARS-CoV-2 and influenza A, but not influenza B.

AstraZeneca Moves To Join Invyvid In COVID-19 Prevention

 
• By Elizabeth Cairns

The UK giant’s COVID-19 prophylactic sipavibart could soon reach Europe and competition is sparse.    

Stock Watch: Thoroughly Moderna Missteps

 
• By Andy Smith

When life hands a biotech company the equivalent of good grapes, the expectations are for its products to be the equivalent of fine wine. Before that Moderna looks likely to make lemonade.

More from Scrip

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance - Clone

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.

Top 10 Drugs Q1 2026: New Sheriff In Town As Mounjaro Unseats Keytruda

Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains